• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Robust survival benefit seen in lupus nephritis patients receiving renal transplant

byKathleen W. HigginsandDeepti Shroff Karhade
January 23, 2019
in Cardiology, Chronic Disease, Nephrology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. For patients with Lupus nephritis end stage renal disease (LN ESRD), renal transplant reduced the risk of death by about 70%.

2. The risk reduction was driven primarily by decreased risk of death from cardiovascular disease and infection.

Evidence Rating Level: 2 (Good)

Study Rundown: Lupus nephritis (LN) is a common consequence of systemic lupus erythematous (SLE), and frequently progresses to end stage renal disease (LN-ESRD).  However, previous studies have raised the concern that kidney transplant and immunosuppression may increase the risk of serious infection and allograft failure in this population.  This cohort study included almost all US patients with LN-ESRD who were waitlisted for a transplant between 1995 and 2014.  When comparing patients who received a transplant to those that did not, the authors found a substantial reduction in all-cause mortality in transplant patient.  Upon closer analysis, this was largely attributable to reductions in deaths due to cardiovascular disease, which included stroke and coronary artery disease, and infection, particularly sepsis.  The reduction was complemented in a subset analysis of Medicare patients, which allowed for closer matching for time-varying comorbid conditions.  Importantly, the same decrease in mortality was seen in African American, Asian, Hispanic, and white patients. This study also addressed complex confounders present in previous studies such as geographic variability.

Strengths of this study include its generalizability and robustness of the analysis. One of the major limitations of the study was that SLE activity prior to transplantation was not accounted for. The study presents important data regarding the survival benefits of renal transplantation for patients with LN and should help inform policy regarding improvements in access to renal transplants.

Click to read the study in Annals of Internal Medicine

Click to read an accompanying editorial in Annals of Internal Medicine

RELATED REPORTS

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus

#VisualAbstract: Voclosporin shows clinical promise for treatment of active lupus nephritis

Relevant Reading: Outcome of renal transplantation in ninety‐seven cyclosporine‐era patients with systemic lupus erythematosus and matched controls

In-Depth [retrospective cohort]: This study evaluated the risk of death for general and specific causes in two cohorts of patients with LN-ESRD who were waitlisted for transplant.  The larger cohort included nearly all American patients with LN-ESRD who were listed during a two-decade period, for a total of 9659 patients.  Of the 59% who received a transplant, the overall risk of death was reduced 70% (adjusted hazard ratio = 0.30).  This was largely attributed to a 74% reduction in risk of death due to cardiovascular disease (HR = 0.26) and a substantially decreased risk of death due to infection (HR = 0.41).  In the subset Medicare cohort, sequential stratification matching was used to compare 2963 patients who received a transplant to 2963 patients who did not.  While the primary analysis controlled only for confounders present at time of waitlisting, the secondary sample also included variable factors like time since initiation of dialysis and time since entry onto the waitlist.  The Medicare patient subset corroborated the earlier results and demonstrated that both deceased-donor and living-donor transplants provide a substantial survival benefit (HR = 0.32 and 0.24, respectively).  The authors also performed a sensitivity analysis that showed that an unrecognized confounder would have to have a hazard ratio of at least 6.1 to explain these data, which strongly supports the observed mortality benefit of renal transplant.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Lupus nephritisrenal transplantsystemic lupus erythematosus (SLE)
Previous Post

Aspirin use associated with reduction in cardiovascular events but increase in bleeding risk

Next Post

Hematopoietic stem cell transplantation reduces transcranial doppler velocities in children with sickle cell anemia

RelatedReports

Multidrug induction therapy increases remission from lupus nephritis
Chronic Disease

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

March 21, 2022
Quick Take: Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Chronic Disease

Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus

November 15, 2021
#VisualAbstract: Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors
StudyGraphics

#VisualAbstract: Voclosporin shows clinical promise for treatment of active lupus nephritis

June 15, 2021
Multidrug induction therapy increases remission from lupus nephritis
Chronic Disease

Voclosporin shows clinical promise for treatment of active lupus nephritis

June 9, 2021
Next Post
The REACH trial: hydroxyurea safe and effective for sickle cell anemia in African children

Hematopoietic stem cell transplantation reduces transcranial doppler velocities in children with sickle cell anemia

Early language exposure is predictive of language skills and IQ in school-age children

Health care use stable after feeding tube placement in children with neurologic impairment

Quick Take: Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents A Voxelwise and Genome-Wide Association Study

Quick Take: Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents A Voxelwise and Genome-Wide Association Study

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.